Cellectar Biosciences (CLRB) Assets Average (2011 - 2026)
Cellectar Biosciences (CLRB) posted Assets Average of $14.8 million for Q4 2025, up 4.53% sequentially from $14.2 million in Q3 2025, and down 52.83% YoY from $31.4 million in Q4 2024.
Cellectar Biosciences (CLRB) Assets Average (2011 - 2026) Analysis & Trends
Cellectar Biosciences has reported Assets Average for 15 years, with the latest figure at $14.8 million in Q4 2025.
- Quarterly Assets Average fell 52.83% year-over-year to $14.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.8 million (down 52.83% YoY) and the FY2025 annual result came in at $20.2 million, up 7.73% from the prior year.
- Assets Average advanced to $14.8 million in Q4 2025 per CLRB's latest filing, from $14.2 million in the prior quarter.
- Over five years, Assets Average peaked at $56.9 million in Q1 2021 and troughed at $10.7 million in Q2 2023.
- A 5-year average of $27.6 million and a median of $25.0 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2023: Assets Average surged 443.09% in 2021, then sank 63.12% in 2023.
- Over 5 years, Assets Average stood at $39.6 million in 2021, then plunged by 48.32% to $20.5 million in 2022, then retreated by 17.8% to $16.8 million in 2023, then surged by 86.66% to $31.4 million in 2024, then plunged by 52.83% to $14.8 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $14.8 million, $14.2 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 25.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.81 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Sep 30, 2025 | 14.16 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 20.76 Mn |
| Dec 31, 2024 | 31.38 Mn |
| Sep 30, 2024 | 33.34 Mn |
| Jun 30, 2024 | 36.15 Mn |
| Mar 31, 2024 | 27.49 Mn |
| Dec 31, 2023 | 16.81 Mn |
| Sep 30, 2023 | 14.03 Mn |
| Jun 30, 2023 | 10.67 Mn |
| Mar 31, 2023 | 18.21 Mn |
| Dec 31, 2022 | 20.45 Mn |
| Sep 30, 2022 | 22.61 Mn |
| Jun 30, 2022 | 28.94 Mn |
| Mar 31, 2022 | 34.60 Mn |
| Dec 31, 2021 | 39.58 Mn |
| Sep 30, 2021 | 44.85 Mn |
| Jun 30, 2021 | 51.40 Mn |